drugset / Trial / NCT00441025

The Effectiveness of Alemtuzumab Combination With CHOP to Treat Patients Newly Diagnosed With PTCL

NCT00441025

Phase 2 Terminated 4 enrolled Mahidol University Bayer · collab
Non-randomizedSingle-groupOpen-labelTreatment

Summary

The purpose of this study is to determine whether the treatment of Alemtuzumab in combination with CHOP(cyclophosphamide,doxorubicin,vincristine and prednisolone) are effective as first line treatment in patients with peripheral T-cell lymphoma.

Timeline

Start
2006-09
Primary completion
Completion
2009-08

Drugs

EvaluationDrugModalityDoseRoute
Comparator Alemtuzumab Monoclonal antibody